CVS Health shares reverse course premarket, last down 7.3%

CVS Health (NYSE: CVS) shares reversed course in premarket trading, last down 7.3%, amid ongoing scrutiny from federal lawmakers. The decline follows an investigation launched by House Oversight Committee Chair James Comer and Federal Law Enforcement Subcommittee Chair Clay Higgins, who are examining whether the company violated HIPAA privacy laws by using confidential patient data in a political lobbying campaign against a Louisiana bill. The probe has raised concerns about potential legal and regulatory consequences, contributing to the sharp sell-off.

The recent drop contrasts with earlier positive momentum for the stock, which has outperformed the managed-care sector since early 2025. In Q2 2026, CVS reported earnings that exceeded expectations, driven by a decline in health benefit costs as a share of premiums. The company also raised its full-year outlook, albeit by a smaller margin than the Q2 beat. Additionally, CVS has introduced new initiatives such as CVS CostVantage and CVS Caremark TrueCost, aiming to enhance transparency in pharmacy reimbursement and improve consumer affordability.

Despite the current volatility, the stock remains near its 52-week high of $74.09, with shares trading at $69.81 as of August 5, 2026. The company has also increased its quarterly dividend by approximately 10%, signaling confidence in its financial stability. Investors are now weighing the potential impact of the ongoing investigation against the company’s broader strategic initiatives and long-term growth prospects.